EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

Objectives: Evaluating the effectiveness of 2 therapeutic schemes for chronic hepatitis C (genotype 6) which combined sofosbuvir and ribavirin, one of them also included pegylated interferon. Materials and methods: The study included 110 patients with chronic hepatitis C (genotype 6), who have undergone antiviral therapy (HTP) in Hepatology Clinic inHo Chi Minh City,Vietnamfrom November 2015 to July 2016. 24 patients were treated by Pegylated interferon alfa-2a, ribavirin and sofosbuvir for 12 weeks, 86 patients – by sofosbuvir and ribavirin for 24 weeks. Non-interferon regimen was administered primarily to patients with contraindications to the use of interferon. To monitor the effectiveness of antiviral therapy, quantification of HCV RNA in serum was performed by PCR prior to treatment, at 4th, 12th or 24th week (depending on the observation group) from the starting of treatment and at 12th, 24th week after completion of treatment. Results: All patients, who were treated with pegylated interferon, ribavirin and sofosbuvir, completed the full course of treatment and 100% of them are registered with sustained virological response at 12th and 24th week after the end of antiviral therapy (SVR-12 and SVR-24, respectively). In the group of patients, who treated with ribavirin and sofosbuvir, 97,7% of patients completed full course of treatment (SVR-12 was registered in 93% of patients, and SVR-24 – in 91,9% of patients). Of 75 patients without a history of HCC, SVR24 was registered in 74 people (98,7%), of 11 patients with HCC – in 5 patients (45,5%). SVR-24 was registered in 98% of patients with cirrhosis (F4) without HCC. Conclusion: The results can serve as a justification for the use of these schemes of antiviral therapy for special groups of patients and/or conditions when it is impossible to follow the latest recommendations, which will help to expand the access of patients to effective antiviral therapy for chronic hepatitis C.

1. Messina JP, Humphreys I, Flaxman A, et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology (Baltimore, Md). 2015; 61(1): 77-87.

2. WHO Library Cataloguing-in-Publication Data Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. (http://www.who.int/hepatitis/publications/hepatitis-cguidelines2016/en/)

3. Lioznov D.A., Chung N.H., Nikolaenko S.L., Trung T.B., Lan P.T., Phong N.D. Clinical and laboratory characteristics of chronic hepatitis C in Vietnam on the example of Ho Chi Minh City Hepatology Clinic. Journal Infectology. 2016;8(4):72-78.

4. Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, et al. High prevalence of hepatitis C virus genotype 6 in Vietnam. Asian Pacific journal of allergy and immunology/ launched by the Allergy and Immunology Society of Thailand. 2009; 27: 153–160.

5. Pham VH, Nguyen HD, Ho PT, Banh DV, Pham HL, et al. Very high prevalence of hepatitis C virus genotype 6 variants in southern Vietnam: large scale survey based on sequence determination. Japanese journal of infectious diseases. 2011; 64: 537–539.

6. Tanimoto T, Nguyen HC, Ishizaki A, Chung PT, Hoang TT, et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. J Med Virol. 2010; 82: 1355–1363.

7. Al Naamani K, Al Sinani S, Deschenes M. Epidemiology and treatment of hepatitis C genotypes 5 and 6. Canadian Journal of Gastroenterology. 2013; 27(1): e8-e12.2.

8. Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World Journal of Hepatology. 2013; 5(9): 496504.

9. Lioznov D., Chung N.H., Nikolaenko S.L. Treatment of chronic hepatitis C (genotype 6) in patients with contraindications to interferon-alfa. Journal Infectology. 2015;7(4):100-102.

10. EASL. Recommendations on treatment of hepatitis C. April, 2014. (http://files.easl.eu/easl-recommendations-ontreatmentof-hepatitis-c-summary.pdf)

11. EASL 2015. HCV treatment recommendations. J Hepatol Express 2015 World Health Organisation (WHO). Hepatitis C – Fact sheet. Updated July 2016. (http://www.who.int/mediacentre/factsheets/fs164/en/)

12. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Study of the Liver. J Hepatol. 2017 Jan;66(1):153-194.